A Phase III, Single-arm Study to Evaluate the Efficacy and Safety of ONCOFID-P-B (Paclitaxel-hyaluronic Acid Conjugate) Administered Intravesically to Patients With BCG-unresponsive Carcinoma in Situ of the Bladder With or Without Ta-T1 Papillary Disease (Orion-BC)
Latest Information Update: 13 May 2024
At a glance
- Drugs Paclitaxel-hyaluronic acid conjugate (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Sponsors Fidia Farmaceutici
- 18 Jan 2023 Status changed from not yet recruiting recruiting.
- 18 Jan 2023 Planned End Date changed from 1 Jul 2027 to 1 Nov 2027.
- 18 Jan 2023 Planned primary completion date changed from 1 Jul 2025 to 1 Nov 2025.